Ovid's Q2 2026: Cash Runway to 2029, OV329 Phase 2 Underway, and a Soticlestat Deal Worth Up to $294.5M
OVID has more than doubled off its 52-week low of $0.534.
Summary
Ovid Therapeutics reported Q2 2026 results with a $15.0M net loss but a strong cash position of $169.8M, extending runway into 2029. The company initiated Phase 2 for OV329 and secured a soticlestat deal worth up to $294.5M in milestones.
Key Events · Earnings and Guidance · OVID
-
Q2 2026 Financial Results
Net loss of $15.0 million, or $0.08 per share, compared to a net loss of $4.7 million, or $0.06 per share, in Q2 2025. R&D expenses rose to $10.0 million from $6.5 million, driven by OV329 and OV4071 clinical activities.
-
Cash Runway Extended to 2029
Cash, cash equivalents and marketable securities totaled $169.8 million as of June 30, 2026, up from $90.4 million at year-end 2025. Management expects this to fund operations into 2029.
-
OV329 Phase 2 Initiated
Initiated a global Phase 2 randomized, placebo-controlled study of OV329 in treatment-resistant focal onset seizures, with completion anticipated in the second half of 2027. Also initiated a photosensitivity study with results expected near year-end 2026.
-
Soticlestat Monetization Deal
Ovid and Takeda assigned global rights to soticlestat to a new company launched by Perceptive Advisors. Ovid is eligible for up to $294.5 million in milestone payments plus low- to mid-single digit royalties on net sales.
Analysis · OVID · Life Sciences
The second quarter of 2026 brought a net loss of $15.0 million for Ovid Therapeutics, but the more important development is the company's strengthened cash position of $169.8 million, which extends its runway into 2029. A Phase 2 proof-of-concept study for OV329 in treatment-resistant focal onset seizures has also been initiated, and a transaction with Perceptive Advisors could deliver up to $294.5 million in milestone payments plus royalties from soticlestat. The exercise of Series A warrants generated $53.9 million in proceeds, further bolstering the balance sheet. These developments reduce near-term financing risk and advance the pipeline, making this a notable update for investors.
At the time of this filing, OVID was trading at $2.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $489M. The 52-week trading range was $0.53 to $3.11. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.